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URPOSE: To report a case series of patients with the nonexposed variant of bisphosphonate-associated
steonecrosis of the jaw—a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/
ucosal fenestration.
ETHODS: Among 332 individuals referred to 5 clinical centers in Europe because of development of
awbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who
resented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes;
adiological investigations; patients’ history, and referral letters.
ESULTS: The most common clinical feature of nonexposed osteonecrosis was jaw bone pain (88/96; 91.6%);
ollowed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological
bnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed osteonecrosis
ubsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6).
ONCLUSIONS: Clinicians should be highly vigilant to identify individuals with nonexposed osteonecrosis,
s the impact on epidemiological data and clinical trial design could be potentially significant. Although
he present case series represents approximately 30% of all patients with bisphosphonates-associated
steonecrosis observed at the study centers, further population-based prospective studies are needed to
btain robust epidemiological figures.
2010 Elsevier Inc. All rights reserved. • The American Journal of Medicine (2010) 123, 1060-1064
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ed.2010.04.033steonecrosis of the jaws is an increasingly common and
linically significant complication of bisphosphonate med-
cations.1-3 Since 2003, more than 1000 cases of bisphos-
honate-associated osteonecrosis of the jaw have been doc-
mented in the literature,1-12 and more than 3500 cases have
een reported to the Food and Drug Administration in the
S alone.4,5 Reported prevalence ranges substantially from
.01% to 28%,1-9 and high variability persists after correc-
ion for type/potency of bisphosphonates and underlying
iseases (high-potency intravenous in cancer patients vs.
ow-potency oral bisphosphonates in osteoporosis pa-
ients).1-9 This is more likely to reflect inconsistency and
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1061Fedele et al Non-exposed Bisphosphonate-associated Osteonecrosis of the Jawaws in the collection of data rather than real variations in
he prevalence among populations.7
The lack of specific diagnostic criteria and a unani-
ously accepted definition of bisphosphonate-associated
steonecrosis of the jaw is possibly the major cause of
his epidemiological inconsistency.
sually, bisphosphonate-associated
steonecrosis of the jaw is defined
s an area of exposed bone in the
axillofacial region that does not
eal within 6-8 weeks in a patient
ho is receiving or has been ex-
osed to bisphosphonate medica-
ions (but not to radiotherapy to
he head and neck).1-8,13 It has
een described as avascular bone
ecrosis from histopathology re-
orts, although biopsy is usually
ot required for its diagnosis.1-3,13
ore recently, however, there
ave been reports suggesting that
isphosphonate-associated osteo-
ecrosis of the jaw, especially in
ts early stages, can manifest signs
nd symptoms in absence of bone
xposure.2,14-16 Jaw bone pain, si-
us tract and gingival/bone swell-
ng in the absence of obvious den-
al or jawbone disease other than osteonecrosis have
ccasionally been reported weeks or months before the
nset of frank bone exposure.14-16 Transient, early-stage
possible bisphosphonate-associated osteonecrosis of the
aws” and a “nonexposed variant of osteonecrosis” have
een proposed as terms for describing this manifesta-
ion.2,14-16 There remain, however, few studies describing in
etail such clinical features and little evidence regarding
heir frequency and natural history.
We studied a series of patients who, after exposure to
isphosphonates, developed jawbone symptoms/signs in ab-
ence of obvious bone exposure for whom no cause other
han osteonecrosis could be identified.
ETHODS
etween 2007 and 2009, 332 individuals had been re-
erred to 5 clinical centers in Europe with possible diag-
osis of bisphosphonate-associated osteonecrosis of the
aw because of development of jawbone abnormalities
fter/during exposure to bisphosphonate medications. A
otal of 96 patients (29.8%) presented jawbone manifes-
ations that fulfilled the description of presumed nonex-
osed variant of bisphosphonate-associated osteonecrosis
f the jaws, as described in previous reports.2,14-16 Rel-
vant clinical features included: 1) jaw pain, 2) jaw bone
nlargement/gingival swelling, and 3) sinus tract, which
ould not be related to dental disease or another local or
CLINICAL SIGNIF
● Bisphosphonates
crosis of the jaw
clinical evidence
posure.
● Clinical features
necrosis include
pain, bone enlar
ing, or sinus trac
dental disease.
● Up to half of th
posed osteonecro
to develop frank
one third would
logical abnormalystemic disorder other than osteonecrosis. mExclusion of dental or primary bone disease other than
steonecrosis was based on clinical and radiological assess-
ent. Patients’ characteristics are presented in Table 1.
Relevant details of nonexposed bisphosphonate-associ-
ted osteonecrosis of the jaws were obtained via clinical
notes, patients’ histories, and re-
ferral letters. The average fol-
low-up from osteonecrosis diag-
nosis to final data collection was
12.6 months (range 6-24 months).
Presence of radiological abnormali-
ties detected with an orthopantomo-
gram or computed tomography, and
subsequent development of trans-
mucosal necrotic bone exposure,
where present, were also recorded.
Hospital and primary care records
were reviewed to collect details of
medical and drug history (including
underlying disease, type and dura-
tion of bisphosphonate therapy), as
well as surgical procedure to the
jaw bones before osteonecrosis
development. We used the defini-
tion of spontaneous nonexposed
bisphosphonate-associated osteo-
necrosis of the jaws when there
was no history of dental surgery to
he affected area over the 6 months preceding osteonecrosis
evelopment.
ESULTS
inety-six (28.9%) of 332 (71.1%) patients were diagnosed
ith nonexposed bisphosphonate-associated osteonecrosis
f the jaws (Table 1). Thirty were male and 66 female, and
heir age ranged from 38 to 90 years (mean: 68 years, 95%
onfidence interval [CI], 66-71). The underlying diseases
hat required treatment with bisphosphonate included mul-
iple myeloma (43 patients, 44.8%), osteoporosis (25 pa-
ients, 26.04%), metastasizing breast cancer (19 patients,
9.8%), prostate cancer (5 patients, 5.2%), and renal cancer
4 patients, 4.2%) (Table 1).
Eighteen patients (18.8%) had been exposed to alendro-
ate only, whereas 39 had zoledronate (40.6%) and 12
atients had pamidronate (12.5%) monotherapies. Four pa-
ients were exposed to clodronate (4.2%), 12 individuals
12.5%) used both pamidronate and zoledronate, and the
emaining patients were exposed to various associations of
lendronate, zoledronate, pamidronate, clodronate, and ibandr-
nate (Table 1).
The mean duration of bisphosphonate therapy before
iagnosis of nonexposed osteonecrosis was 37.0 months
range 5-120 months; 95% CI, 31.6-42.5). In 21 patients
21.8%) the duration was 5-12 months, while 23 individ-
als (23.9%) had taken bisphosphonates for 13-24
CE
ciated osteone-
present with no
ecrotic bone ex-
onexposed osteo-
istent jaw bone
nt, gingival swell-
bsence of relevant
ients with nonex-
ay never progress
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1062 The American Journal of Medicine, Vol 123, No 11, November 2010steonecrosis of the jaw was diagnosed. Exposure to
5-36 and 37-60 months of bisphosphonate therapy was
ssociated with jaw osteonecrosis in 12 (12.5%) and 20
20.8%)patients, respectively. Twenty-one individuals
21.8%) had used bisphosphonate for more than 60
onths before bisphosphonate-associated osteonecrosis
f the jaw occurred. In total, 44 (45.8%) individuals had
history of bisphosphonate exposure 24 months before
he development of symptoms or signs of nonexposed
steonecrosis (Table 1, Figure).
In the subgroup of patients who had used only alendro-
ate, we observed that the length of therapy before diagno-
is of bisphosphonate-associated osteonecrosis of the jaw
anged from 12 to 96 months (mean 62.8; 95% CI, 47.1-
8.5). Patients who developed nonexposed jaw osteonecro-
is after exposure to zoledronic acid or pamidronate only
id so after 8-62 (mean 24.1; 95% CI, 16.1-32.0) and 5-120
onths of therapy (mean 45.3; 95% CI, 18.6-65.9),
espectively.
Overall, the most common clinical feature of nonexposed
steonecrosis was jaw bone pain, which was reported by 88
atients (91.6%), followed by sinus tract formation (49
atients, 51%), bone enlargement (35 patients, 36.4%), and
ingival enlargement (17 patients, 17.7%) (Table 2). These
Table 1 Characteristics of Patients and Type and Duration of B
isease Patients n (%)
Sex and Mean Age,
Years (Range)
ultiple myeloma 43 (44.8%) 22 F
21 M
68.9 (50-82)
steoporosis 25 (26.0%) 24 F
1 M
68.96 (38-88)
etastasizing
reast cancer
19 (17.85%) 19 F
64.2 (43-85)
etastasizing
rostate cancer
5 (5.2%) 5 M
76 (72-90)
etastasizing
enal cancer
4 (4.2%) 3 M
1 F
67.5 (56-69)ymptoms/signs developed spontaneously in all patients,ith no history of dental surgery during the previous 6
onths having been reported.
phonate Therapy before Development of Osteonecrosis
phosphonate Therapy
o. of Patients)
Mean and Median Duration of
Bisphosphonate Therapy
before Osteonecrosis
Development (Months)
ledronate (23)
midronate (8)
midronate zoledronate (8)
dronate (1)
ndronate zoledronate (1)
midronate clodronate (1)
ndronate pamidronate (1)
Mean: 35.02
Median: 25
ndronate (18)
dronate (3)
ledronate (1)
midronate (2)
adronate (1)
Mean: 57.28
Median: 60
ledronate (8)
midronate zoledronate (3)
midronate (3)
ledronate clodronate (2)
ledronate ibandronate (2)
midronate zoledronate
ndronate ibandronate (1)
Mean: 38.94
Median: 24
ledronate (4)
midronate zoledronate (1)
Mean: 23.0
Median: 27
ledronate (4) Mean: 20.52
Median: 18
Figure Scatter plot of patients affected by nonexposed os-
teonecrosis categorized by underlying disease and with detail
of bisphosphonate agents (oral vs. intravenous) and therapy
duration. The horizontal lines indicate the median values of
therapy duration in each disease group. BC breast cancer;
MMmultiple myeloma; OST osteoporosis; PC prostateisphos
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1063Fedele et al Non-exposed Bisphosphonate-associated Osteonecrosis of the JawTwenty-eight patients (29.1%) had no demonstrable ra-
iological abnormalities (orthopantomogram or computed
omography scan), whereas 68 (70.9%) had evidence of
steolysis with/without osteosclerosis (Table 2).
In 51 patients (53.1%) nonexposed osteonecrosis subse-
uently progressed into frank bone exposure over a period
f time ranging from 0.5 to 14 months (mean 4.6; 95% CI,
.6-5.6). Such a progression was not observed in the re-
aining 45 patients (46.9%), who did not develop obvious
vidence of bone exposure throughout the observation pe-
iod (up to 2 years).
ISCUSSION
he present observational study is the largest published
eries of patients who had been exposed to bisphosphonates
nd developed jaw bone symptoms/signs in the absence of
one exposure. These patients were classified as being af-
ected by nonexposed bisphosphonate-associated osteone-
rosis of the jaw because: 1) there was no obvious evidence
f dental infection or other jaw bone disease (eg, metasta-
es) that could cause those symptoms/signs, and 2) some of
hem subsequently developed frank bone exposure.
Although most studies define bisphosphonate-associated
steonecrosis of the jaws as an area of long-lasting exposed
ecrotic bone, the existence of a nonexposed variant of
steonecrosis has been recently suggested.2,14-16 The ratio-
ale behind this definition is based on the hypothesis that
he osteonecrosis might develop within the bone marrow,
otentially causing pain, bone enlargement/gingival swell-
ng, and sinus tract due to intrabony edema/inflammation, in
he absence of frank mucosal fenestration and bone expo-
ure.12 Necrotic bone exposure could then occur spontane-
usly or following exposure to local triggering factors, such
Table 2 Summary of Clinical and Radiological Features of Non
enter
Total Cases of
Nonexposed BONJ
(n Patients)
Manifestations
Jaw Bone Pain
(n Patients)
Bone
Enlargemen
(n Patients)
CL EDI 8 6 1
SP 20 20 19
MSI 28 25 13
MT 6 5 2
OMPLAS-PR 34 32 0
otal, n (%) 96 88 (91.6%) 35 (36.4%)
BONJ bisphosphonate-associated osteonecrosis of the jaws; OMSI
Hashomer, Israel; OMT Department of Oral Medicine, Lingotto Dental I
Italy; UCL EDI University College London Eastman Dental Institute, UKs surgery or trauma. iModels of osteonecrosis of the hip17 and other long
ones18 provide evidence for this hypothesis, which is also
upported by recent experimental demonstration of devel-
pment of nonexposed intrabony medullar necrosis in dogs
xposed to bisphosphonates.19,20 Only 2 clinical human
tudies have reported a small number (n7) of patients
ith a nonexposed variant of bisphosphonate-associated
steonecrosis of the jaw. Mawardi et al15 and Junquera and
allego16 described 5 and 2 patients, respectively, who had
een exposed to bisphosphonates and subsequently devel-
ped pain, bone enlargement/gingival swelling, and tooth
obility with no evidence of necrotic bone exposure and no
bvious dental disease. All patients but one showed radio-
ogical abnormalities and developed subsequently frank
one exposure.15,16 In addition, a transient early stage of
isphosphonate-associated osteonecrosis of the jaws de-
cribed as nonexposed variant was included in recent
lassifications.21-23
The present case series differs from previous reports be-
ause abnormal radiological findings were not considered a
ecessary diagnostic criterion for bisphosphonate-associated
steonecrosis of the jaws and the nonexposed variant proved to
e a separate entity per se in approximately 50% of patients.
owever, we cannot draw firm conclusions as it cannot be
xcluded that frank bone exposure would occur at a later time
ollowing the onset of nonexposed osteonecrosis. Similarly, as
ore advanced diagnostic tests such as magnetic resonance
maging and bone scintigraphy were not consistently available,
e cannot exclude that early radiological abnormalities could
e identified in the affected areas.
Nevertheless, our observations would suggest that the
elative frequency of nonexposed versus traditional exposed
isphosphonate-associated osteonecrosis of the jaw is clin-
d BONJ
Progression to Frank
Bone Exposure
(n Patients)
gival
elling
Patients)
Sinus Tract
(n Patients)
Radiological
Abnormalities
(n Patients)
6 1 Yes (3)
No (5)
1 1 Yes (18)
No (2)
24 8 Yes (21)
No (7)
2 4 Yes (5)
No (1)
16 14 Yes (4)
No (30)
(17.7%) 49 (51%) 28 (29.1%) Yes (51; 53.2%)
No (45; 46.8%)
rtment of Oral and Maxillofacial Surgery, Sheba Medical Center, Tel-
, Turin, Italy; OSP Department of Oral Sciences of Palermo University,
AS-PR Unit of Oral Medicine Pathology Laser-Assisted Surgery–Parma.expose
t
Gin
Sw
(n
2
1
13
1
0
17
 Depa
nstitutecally relevant (one third of all osteonecrosis cases observed
au
o
t
e
i
c
s
p
o
fi
s
A
T
U
p
t
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
1064 The American Journal of Medicine, Vol 123, No 11, November 2010t the 5 clinical centers), although further prospective pop-
lation-based studies are required.
Clinicians should be aware that a significant proportion
f patients with bisphosphonate-associated osteonecrosis of
he jaw could present with persistent jaw bone pain, bone
nlargement, gingival swelling, or sinus tract before or
nstead of frank bone exposure. Further, only 50% of the
ases of nonexposed bisphosphonate-associated osteonecro-
is of the jaws would subsequently progress to frank ex-
osed osteonecrosis, and up to one third would show no
bvious radiological abnormalities. The impact of these
ndings upon epidemiological data and the design of future
tudies could be significant.
CKNOWLEDGMENT
his work was undertaken at University College London/
niversity College London Hospital, which received a pro-
ortion of funding from the Department of Health’s Na-
ional Institute for Health Research Biomedical Research
entre funding scheme.
eferences
1. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated os-
teonecrosis: a long-term complication of bisphosphonate treatment.
Lancet Oncol. 2006;7:508-514 (Erratum in: Lancet Oncol. 2006;7:
533).
2. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of
bisphosphonates: a critical review. Am J Med. 2009;122:S33-S45.
3. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review:
bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;
144:753-761 (Erratum in: Ann Intern Med. 2006;145:235).
4. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and
reporting oversight in US FDA fast-track process: bisphosphonates
and osteonecrosis of the jaw. Lancet Oncol. 2008;9:1166-1172.
5. Research on Adverse Drug Reactions and Reporting (RADAR).
Bisphosphonate associated osteonecrosis of the jaw: FDA AERS
search. Available at: http://cancer.northwestern.edu/radar/yearsONJ
forradarwebsite.pdf. Accessed December 13, 2009.
6. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study
of risk factors in cancer patients of bisphosphonate-related osteone-
crosis of the jaw. J Clin Oncol. 2009;27:5356-5362.
7. Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-
induced osteonecrosis of the jaws: prospective study of 80 patients
with multiple myeloma and other malignancies. Oral Oncol. 2008;44:
857-869.8. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in
cancer after treatment with bisphosphonates: incidence and risk fac-
tors. J Clin Oncol. 2005;23:8580-8587.
9. Badros A, Terpos E, Katodritou E, et al. Natural history of osteone-
crosis of the jaw in patients with multiple myeloma. J Clin Oncol.
2008;26:5904-5909.
0. Kyrgidis A, Vahtsevanos K. Osteonecrosis of the jaw in patients
receiving oral bisphosphonates. Osteoporos Int. 2010;21:535-536.
1. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related
osteonecrosis of the jaws: clinical findings, assessment of risks, and
preventive strategies. J Oral Maxillofac Surg. 2009;67:35-43.
2. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A
review of the literature on osteonecrosis of the jaw in patients with
osteoporosis treated with oral bisphosphonates: prevalence, risk fac-
tors, and clinical characteristics. Clin Ther. 2007;29:1548-1558.
3. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced ex-
posed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors,
recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;
63:1567-1575.
4. Bagan JV, Jimenez Y, Diaz JM, et al. Osteonecrosis of the jaws in
intravenous bisphosphonate use: proposal for a modification of the
clinical classification. Oral Oncol. 2009;45:645-646.
5. Mawardi H, Treister N, Richardson P, et al. Sinus tracts—an early sign
of bisphosphonate-associated osteonecrosis of the jaws? J Oral Max-
illofac Surg. 2009;67:593-601.
6. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteone-
crosis of the jaws: another clinical variant? J Oral Maxillofac Surg.
2008;66:1516-1517.
7. Malizos KN, Karantanas AH, Varitimidis SE, et al. Osteonecrosis of
the femoral head: etiology, imaging and treatment. Eur J Radiol.
2007;63:16-22.
8. Harreld KL, Marker DR, Wiesler ER, et al. Osteonecrosis of the
humeral head. J Am Acad Orthop Surg. 2009;17:345-355.
9. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of
zoledronic acid result in near-complete suppression of mandible intra-
cortical bone remodeling in beagle dogs. J Bone Miner Res. 2010;
25(1):98-105.
0. Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with
bisphosphonates. Orthod Craniofac Res. 2009;12:221-228.
1. American Dental Association Council on Scientific Affairs. Dental
management of patients receiving oral bisphosphonate therapy: expert
panel recommendations—report of the Council on Scientific Affairs.
Available at: www.ada.org/prof/resources/topics/topics_osteonecrosis_
bisphosphonate_report.pdf. Accessed November 13, 2009.
2. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of
Oral and Maxillofacial Surgeons position paper on bisphosphonate-
related osteonecrosis of the jaws—2009 update. J Oral Maxillofac
Surg. 2009;67:2-12.
3. McMahon RE, Bouquot JE, Glueck CJ, et al. Staging bisphosphonate-
related osteonecrosis of the jaw should include early stages of disease.
J Oral Maxillofac Surg. 2007;65:1899-1900.
